Voyager Therapeutics (NASDAQ:VYGR) Earns “Buy” Rating from HC Wainwright

Voyager Therapeutics (NASDAQ:VYGR)‘s stock had its “buy” rating reaffirmed by investment analysts at HC Wainwright in a research note issued on Thursday,Benzinga reports. They presently have a $30.00 target price on the stock.

A number of other research analysts have also recently issued reports on the stock. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $14.00 price target on shares of Voyager Therapeutics in a report on Thursday, November 14th. Wells Fargo & Company set a $10.00 target price on shares of Voyager Therapeutics and gave the stock an “overweight” rating in a report on Wednesday. Citigroup began coverage on shares of Voyager Therapeutics in a report on Monday, December 2nd. They set a “buy” rating and a $12.00 target price for the company. StockNews.com cut shares of Voyager Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, December 13th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Voyager Therapeutics in a report on Wednesday. One investment analyst has rated the stock with a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $14.86.

Voyager Therapeutics Trading Down 4.2 %

NASDAQ VYGR opened at $3.90 on Thursday. The company has a fifty day simple moving average of $4.88 and a two-hundred day simple moving average of $5.85. The stock has a market cap of $213.04 million, a P/E ratio of 5.49 and a beta of 0.99. Voyager Therapeutics has a 12-month low of $3.56 and a 12-month high of $10.66.

Voyager Therapeutics (NASDAQ:VYGR) last posted its quarterly earnings results on Tuesday, March 11th. The company reported ($0.59) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.24). The company had revenue of $4.39 million during the quarter, compared to analysts’ expectations of $16.58 million. Voyager Therapeutics had a return on equity of 8.33% and a net margin of 15.80%. During the same period in the prior year, the business posted $1.25 EPS. As a group, sell-side analysts forecast that Voyager Therapeutics will post -0.91 earnings per share for the current year.

Insider Buying and Selling at Voyager Therapeutics

In other news, COO Robin Swartz sold 6,500 shares of the business’s stock in a transaction dated Monday, December 23rd. The shares were sold at an average price of $5.65, for a total transaction of $36,725.00. Following the completion of the sale, the chief operating officer now owns 112,328 shares of the company’s stock, valued at $634,653.20. The trade was a 5.47 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Over the last quarter, insiders sold 10,778 shares of company stock valued at $58,548. Corporate insiders own 4.53% of the company’s stock.

Institutional Trading of Voyager Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. Geode Capital Management LLC increased its stake in shares of Voyager Therapeutics by 0.6% during the third quarter. Geode Capital Management LLC now owns 1,079,509 shares of the company’s stock worth $6,316,000 after purchasing an additional 6,740 shares in the last quarter. FMR LLC increased its stake in shares of Voyager Therapeutics by 26.9% during the third quarter. FMR LLC now owns 92,498 shares of the company’s stock worth $541,000 after purchasing an additional 19,622 shares in the last quarter. Barclays PLC increased its stake in shares of Voyager Therapeutics by 55.8% during the third quarter. Barclays PLC now owns 104,462 shares of the company’s stock worth $612,000 after purchasing an additional 37,398 shares in the last quarter. Allspring Global Investments Holdings LLC increased its stake in shares of Voyager Therapeutics by 23.9% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 39,313 shares of the company’s stock worth $223,000 after purchasing an additional 7,573 shares in the last quarter. Finally, Verition Fund Management LLC purchased a new stake in shares of Voyager Therapeutics during the third quarter worth about $216,000. Hedge funds and other institutional investors own 48.03% of the company’s stock.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.